Alfred Mann Foundation spinout Axonics Modulation Technologies raises nearly $33 million in a Series A round for its neuromodulation technology.
Axonics Modulation Technologies said it drummed up a $32.6 million Series A round for the neuromodulation technology it's developing to treat chronic pain and overactive bladder.
Irvine, Calif.-based Axonics said the round was led by Edmond de Rothschild Investment Partners and included NeoMed Management, Legend Capital and "a select group of private individuals."
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1ftEUiK
Cap comentari:
Publica un comentari a l'entrada